Eligibility for Anti‐Amyloid‐β Monoclonal Antibodies in Patients With Primary Progressive Aphasia due to Alzheimer's Disease in Japan
Psychogeriatrics · 2026
DOI: 10.1111/psyg.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychogeriatrics, 2026. Verfasst von Shoya Inagawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Aphasia, Primary Progressive, Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Primary progressive aphasia (PPA) is a clinical syndrome characterized by progressive language impairment. The logopenic variant (lvPPA) is frequently associated with Alzheimer's disease (AD) pathology. With the approval of anti‐amyloid‐β monoclonal antibodies, such as lecanemab and donanemab, for the treatment of AD, accurately differentiating lvPPA due to AD (lvAD) from the other PPA variants has become highly important.
Methods
Thirteen patients with PPA who underwent cognitive testing, including the Standard Language Test of Aphasia (SLTA), brain magnetic resonance imaging, single‐photon emission computed tomography (SPECT), cerebrospinal fluid (CSF) biomarker analysis, and amyloid positron emission tomography (PET) imaging were enrolled in this study. Patients were classified into the lvPPA, semantic variant PPA (svPPA), and nonfluent/agrammatic variant PPA (nfaPPA) groups based on the results of clinical and neuropsychological assessments. We determined the proportion of PPA patients in each group who met the optimal use guidelines for anti‐amyloid monoclonal antibody therapy.
Results
Six (86%) of the 7 lvPPA patients were amyloid positive (A+), and 5 (71%) were eligible for lecanemab or donanemab. In most lvPPA patients, SPECT displayed an AD‐typical pattern of hypoperfusion in the bilateral temporoparietal regions, posterior cingulate gyrus, and precuneus. One lvPPA patient was negative for AD biomarkers and demonstrated an atypical perfusion pattern for AD, and was subsequently rediagnosed as having frontotemporal lobar degeneration.
Conclusions
These results suggest that SPECT may play a supportive role in differentiating lvAD from PPA. In the current clinical era of anti–amyloid‐β monoclonal antibody therapy, accurate identification of lvAD among patients with language‐predominant symptoms is increasingly important. Larger studies should be performed in the near future to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.
- Department of Radiology, Tokyo Medical University, Tokyo, Japan.
- Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.
- Brain Research Institute, Niigata University, Niigata, Japan.
- Department of Diagnostic Innovation Science, National Center for Geriatrics and Gerontology, Aichi, Japan.
ORCID-Profile: Kazuhiro Saito, Takeshi Ikeuchi
Zitieren
APA
Inagawa, S., Inagawa, Y., Tsugawa, A., Takenoshita, N., Saito, K., Ishii, K., Kasuga, K., Ikeuchi, T., & Shimizu, S. (2026). Eligibility for Anti‐Amyloid‐β Monoclonal Antibodies in Patients With Primary Progressive Aphasia due to Alzheimer's Disease in Japan. Psychogeriatrics. https://doi.org/10.1111/psyg.70152
Vancouver
Inagawa S, Inagawa Y, Tsugawa A, Takenoshita N, Saito K, Ishii K, et al. Eligibility for Anti‐Amyloid‐β Monoclonal Antibodies in Patients With Primary Progressive Aphasia due to Alzheimer's Disease in Japan. Psychogeriatrics. 2026. doi:10.1111/psyg.70152
BibTeX
@article{Inagawa2026,
author = {Inagawa, Shoya and Inagawa, Yuta and Tsugawa, Akito and Takenoshita, Naoto and Saito, Kazuhiro and Ishii, Kenji and Kasuga, Kensaku and Ikeuchi, Takeshi and Shimizu, Soichiro},
title = {Eligibility for Anti‐Amyloid‐β Monoclonal Antibodies in Patients With Primary Progressive Aphasia due to Alzheimer's Disease in Japan},
journal = {Psychogeriatrics},
year = {2026},
doi = {10.1111/psyg.70152}
}
EUVIMED